Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/04/19
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 08/20/20
End: 01/18/24
Due: 01/18/25
Phase: N/A
Priority: Normal
Start: 06/05/20
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 12/18/30
End: 06/18/34
Due: 06/18/35
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| 9-ING-41 in Patients with Advanced Cancers | NCT03678883 | Actuate Therapeutics Inc. | user2@example.com | None | 2019-01-04 | 2026-01-31 | 2027-01-31 | - | - | 2025-07-14 |
| Actuate 1901: 9-ING-41 in Myelofibrosis | NCT04218071 | Actuate Therapeutics Inc. | user2@example.com | None | 2020-08-20 | 2024-01-18 | 2025-01-18 | - | - | 2025-07-14 |
| 9-ING-41 in Pediatric Patients with Refractory Malignancies. | NCT04239092 | Actuate Therapeutics Inc. | user2@example.com | None | 2020-06-05 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | NCT04832438 | Actuate Therapeutics Inc. | user2@example.com | None | 2030-12-18 | 2034-06-18 | 2035-06-18 | - | - | 2025-07-14 |